UB Paderborn / Katalog / Suche / in CDI

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

The journal of clinical endocrinology and metabolism, 2009-02, Vol.94 (2), p.545-551

2009

Link zum Volltext

Verfügbarkeit prüfen

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine

Drugs in R&D, 2017-09, Vol.17 (3), p.449-459

2017

Link zum Volltext

Verfügbarkeit prüfen

VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)

Progress in medicinal chemistry, 2018, Vol.57 (1), p.87-111

2018

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects

British journal of clinical pharmacology, 2009-03, Vol.67 (3), p.288-298

2009

Link zum Volltext

Verfügbarkeit prüfen

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic

The Journal of pharmacology and experimental therapeutics, 2004-11, Vol.311 (2), p.547

2004

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902)

The journal of clinical endocrinology and metabolism, 2006-10, Vol.91 (10), p.3903-3907

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

The Journal of pharmacology and experimental therapeutics, 2017-06, Vol.361 (3), p.454

2017

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological Characterization of a Novel Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor, NBI-42902

Endocrinology (Philadelphia), 2007-02, Vol.148 (2), p.857-867

2007

Link zum Volltext

Verfügbarkeit prüfen

Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor

Journal of medicinal chemistry, 2007-12, Vol.50 (25), p.6356-6366

2007

Link zum Volltext

Verfügbarkeit prüfen

Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core

Journal of medicinal chemistry, 2005-06, Vol.48 (12), p.4100-4110

2005

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Obstetrical & gynecological survey, 2009-06, Vol.64 (6), p.386-388

2009

Link zum Volltext

Verfügbarkeit prüfen

Poster Number: NR 31 - Pharmacokinetics of Valbenazine and Its Active Metabolite by Age Group

The American journal of geriatric psychiatry, 2018-03, Vol.26 (3), p.S159-S159

2018

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of Valbenazine and Its Active Metabolite by Age Group

The American journal of geriatric psychiatry, 2018-03, Vol.26 (3), p.S159

2018

Link zum Volltext

Verfügbarkeit prüfen

Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902)

Obstetrical & gynecological survey, 2007-03, Vol.62 (3), p.187-189

2007

Link zum Volltext

Verfügbarkeit prüfen

Neuroprotective Effects of the CRF1 Antagonist R121920 after Permanent Focal Ischemia in the Rat

Journal of cerebral blood flow and metabolism, 2001-10, Vol.21 (10), p.1208-1214

2001

Link zum Volltext

Verfügbarkeit prüfen

Cardiac safety assessment of NBI-1: Potential role of I sub(Ks) potassium channel in the observed QT prolongation detected in vivo

Journal of pharmacological and toxicological methods, 2009-10, Vol.60 (2), p.240-241

2009

Link zum Volltext

Verfügbarkeit prüfen

A pharmacokinetic evaluation of five H 1 antagonists after an oral and intravenous microdose to human subjects

British journal of clinical pharmacology, 2009-03, Vol.67 (3), p.288-298

2009

Link zum Volltext

Verfügbarkeit prüfen

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a] pyrimidine (NBI 30775/r121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

Journal of medicinal chemistry, 2004-09, Vol.47 (19), p.4787-4798

2004

Link zum Volltext

Verfügbarkeit prüfen

Cardiac safety assessment of NBI-1: Potential role of IKs potassium channel in the observed QT prolongation detected in vivo

Journal of pharmacological and toxicological methods, 2009-09, Vol.60 (2), p.240-241

2009

Link zum Volltext

Verfügbarkeit prüfen

A novel on-line solid-phase extraction approach integrated with a monolithic column and tandem mass spectrometry for direct plasma analysis of multiple drugs and metabolites

Rapid communications in mass spectrometry, 2005-01, Vol.19 (22), p.3259-3268

2005

Link zum Volltext

Verfügbarkeit prüfen

3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a Potent and Orally Active Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. Design, Synthesis, and in Vitro and in Vivo Characterization

Journal of medicinal chemistry, 2005-02, Vol.48 (4), p.1169-1178

2005

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists

Bioorganic & medicinal chemistry, 2008-05, Vol.16 (10), p.5606-5618

2008

Link zum Volltext

Verfügbarkeit prüfen

Electrophysiological assessment of the effect of NBI-1 on the action potential kinetics of cardiac human Purkinje fibers in the presence or absence of dofetilide and b-adrenoceptor stimulation

Journal of pharmacological and toxicological methods, 2009-09, Vol.60 (2), p.242-242

2009

Link zum Volltext

Verfügbarkeit prüfen

Rational Design, Synthesis, and Structure−Activity Relationships of Aryltriazoles as Novel Corticotropin-Releasing Factor-1 Receptor Antagonists

Journal of medicinal chemistry, 2005-03, Vol.48 (5), p.1540-1549

2005

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine

VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)

A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects

In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic

Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902)

Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites

Pharmacological Characterization of a Novel Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor, NBI-42902

Design, Synthesis, In Vitro, and In Vivo Characterization of Phenylpiperazines and Pyridinylpiperazines as Potent and Selective Antagonists of the Melanocortin-4 Receptor

Potent, Orally Active Corticotropin-Releasing Factor Receptor-1 Antagonists Containing a Tricyclic Pyrrolopyridine or Pyrazolopyridine Core

Suppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix

Poster Number: NR 31 - Pharmacokinetics of Valbenazine and Its Active Metabolite by Age Group

Pharmacokinetics of Valbenazine and Its Active Metabolite by Age Group

Suppression of Serum Luteinizing Hormone in Postmenopausal Women by an Orally Administered Nonpeptide Antagonist of the Gonadotropin-Releasing Hormone Receptor (NBI-42902)

Neuroprotective Effects of the CRF1 Antagonist R121920 after Permanent Focal Ischemia in the Rat

Cardiac safety assessment of NBI-1: Potential role of I sub(Ks) potassium channel in the observed QT prolongation detected in vivo

Discovery of Sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (Elagolix), a Potent and Orally Available Nonpeptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor

A pharmacokinetic evaluation of five H 1 antagonists after an oral and intravenous microdose to human subjects

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a] pyrimidine (NBI 30775/r121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists

Cardiac safety assessment of NBI-1: Potential role of IKs potassium channel in the observed QT prolongation detected in vivo

A novel on-line solid-phase extraction approach integrated with a monolithic column and tandem mass spectrometry for direct plasma analysis of multiple drugs and metabolites

3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a Potent and Orally Active Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. Design, Synthesis, and in Vitro and in Vivo Characterization

Pharmacological and pharmacokinetic characterization of 2-piperazine-α-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists

Electrophysiological assessment of the effect of NBI-1 on the action potential kinetics of cardiac human Purkinje fibers in the presence or absence of dofetilide and b-adrenoceptor stimulation

Rational Design, Synthesis, and Structure−Activity Relationships of Aryltriazoles as Novel Corticotropin-Releasing Factor-1 Receptor Antagonists

Suchergebnisse filtern